Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis

Blood

Volumn 118, Issue 14, 2011, Pages 4003-4006

  Zheng, Hui ^a   Qian, Juan ^a   Carbone, Christopher J ^a   Leu, N Adrian ^a   Baker, Darren P ^b   Fuchs, Serge Y ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON RECEPTOR; INTERFERON RECEPTOR TYPE 1; PROTEIN KINASE D; PROTEIN KINASE D2; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 80053632555     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-359745     Document Type: Article

References (25)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611. (Pubitemid 39099316)
2. Selleck SB. Signaling from across the way: transactivation of VEGF receptors by HSPGs. Mol Cell. 2006;22(4):431-432.
3. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol. 2007;39(7):1349-1357. (Pubitemid 47031045)
4. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47(19):5155-5161. (Pubitemid 17146488)
5. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296(5573):1653-1655. (Pubitemid 34579157)
6. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375-386. (Pubitemid 40685987)
7. Huangfu WC, Fuchs SY. Ubiquitination-dependent regulation of signaling receptors in cancer. Genes Cancer. 2010;1(7):725-734.
8. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 2003;22(20):5480-5490. (Pubitemid 37279957)
9. Zheng H, Qian J, Varghese B, Baker DP, Fuchs S. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol. 2011;31(4):710-720.
10. McKendry R, John J, Flavell D, Muller M, Kerr IM, Stark GR. High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. Proc Natl Acad Sci U S A. 1991;88(24):11455-11459. (Pubitemid 21916060)
11. Kumar KG, Krolewski JJ, Fuchs SY. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J Biol Chem. 2004;279(45):46614-46620. (Pubitemid 39518306)
12. Goldman LA, Zafari M, Cutrone EC, et al. Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. J Interferon Cytokine Res. 1999;19(1):15-26. (Pubitemid 29070228)
13. Kumar KG, Barriere H, Carbone CJ, et al. Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol. 2007;179(5):935-950. (Pubitemid 350223490)
14. Li Y, Gazdoiu S, Pan ZQ, Fuchs SY. Stability of homologue of Slimb F-box protein is regulated by availability of its substrate. J Biol Chem. 2004;279(12):11074-11080. (Pubitemid 38401599)
15. Marijanovic Z, Ragimbeau J, Kumar KG, Fuchs SY, Pellegrini S. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem J. 2006;397(1):31-38. (Pubitemid 44032833)
16. Soldatenkov VA, Dritschilo A, Ronai Z, Fuchs SY. Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. Cancer Res. 1999;59(20):5085-5088. (Pubitemid 29503963)
17. Liu J, HuangFu WC, Kumar KG, et al. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylationdependent degradation of the type I interferon receptor. Cell Host Microbe. 2009;5(1):72-83.
18. Medhora M, Daniels J, Mundey K, et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol. 2003;284(1):H215-H224. (Pubitemid 36076288)
19. Chiodoni C, Iezzi M, Guiducci C, et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med. 2006;203(11):2441-2450. (Pubitemid 44664614)
20. Fuchs SY. De-regulation of ubiquitin-dependent proteolysis and the pathogenesis of malignant melanoma. Cancer Metastasis Rev. 2005;24(2):329-338. (Pubitemid 40922803)
21. Fuchs SY, Spiegelman VS, Kumar KG. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene. 2004;23(11):2028-2036. (Pubitemid 38496732)
22. Meyer RD, Srinivasan S, Singh AJ, Mahoney JE, Gharahassanlou KR, Rahimi N. PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation. Mol Cell Biol. 2011;31(10):2010-2025.
23. Qin L, Zeng H, Zhao D. Requirement of protein kinase D tyrosine phosphorylation for VEGF-A165-induced angiogenesis through its interaction and regulation of phospholipase Cgamma phosphorylation. J Biol Chem. 2006;281(43):32550-32558. (Pubitemid 46036810)
24. Wong C, Jin ZG. Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J Biol Chem. 2005;280(39):33262-33269. (Pubitemid 41397122)
25. Hao Q, Wang L, Zhao ZJ, Tang H. Identification of protein kinase D2 as a pivotal regulator of endothelial cell proliferation, migration, and angiogenesis. J Biol Chem.. 2009;284(2):799-806.